This site is part of the Siconnects Division of Sciinov Group

This site is operated by a business or businesses owned by Sciinov Group and all copyright resides with them.

ADD THESE DATES TO YOUR E-DIARY OR GOOGLE CALENDAR

Registration

28 Aug
2024

Risks faced by women using anabolic steroids in Australia

A new study published in Drug and Alcohol Review has revealed critical insights into the challenges and risks faced by women who use anabolic-androgenic steroids (AAS).Readmore

10 Sep
2024

Patients receiving steroids are more than twice as likely to develop diabetes, UK study has found

Patients who are being treated with systemic glucocorticoids are more than twice as likely to develop diabetes as those not receiving the treatment, a new study by researchers at the Radcliffe Department of Medicine’s Diabetes Trial Unit has found.Readmore

13 Feb
2024

Anabolic steroid use can increase heart disease risk

Taking testosterone may increase the risk of atrial fibrillation in individuals with an existing predispositionReadmore

3 Jun
2024

Men experience declines in mental health and sexual function during the first year after stopping steroid use

About 65% of men who stop anabolic steroids restart, likely due to withdrawal symptoms. Worsened mental health and sexual function should be targeted during the first year of steroid cessation.Readmore

21 Aug
2024

Sports Controversy:Jannik Sinner Avoids Suspension After Steroid Tests

World No. 1 faces backlash and penalties following two positive doping tests without intentional violationReadmore

25 Apr
2024

Steroid treatment in late pregnancy does not appear to affect children’s neurodevelopment, NICHD-funded study suggests

Neurodevelopmental Outcomes After late preterm antenatal corticosteroids: The ALPS follow-up studyReadmore

13 Feb
2024

Anabolic steroid use can increase heart disease risk: A Researchers led by University of Birmingham

Taking testosterone may increase the risk of atrial fibrillation in individuals with an existing predispositionReadmore

05 Jan
2024

Medical Advancements:Patients on benralizumab for asthma maintain control with reduced corticosteroid doses

Key takeaways: - 96% of patients maintained reductions through 48 weeks. - 91% of patients had no exacerbations while tapering their doses. - The intervention and reference groups had similar rates of adverse events.Readmore

Subscribe to our News & Updates